Cypher, Taxus Perform Equally Well In Trials, Registries – Meier Analysis
This article was originally published in The Gray Sheet
Executive Summary
The overall clinical performance of Boston Scientific's Taxus and J&J/Cordis' Cypher drug-eluting coronary stents is practically equivalent, according to Bernard Meier, MD, University Hospital, Bern, Switzerland